Neoadjuvant chemotherapy has been established as the standard of care for HER2-positive breast cancer since it allows cancer down-staging, up to pathological complete response. The standard of care in the neoadjuvant setting for HER2-positive breast cancer is a combination of highly cytotoxic drugs such as anthracyclines and the anti-HER2 monoclonal antibody. Despite this cocktail allows a pathological complete response in up to 50%, their co-administration is strongly limited by intrinsic cardiotoxicity. Therefore, only a sequential administration of anthracyclines and the anti-HER2 treatment is allowed. Here, we propose the anthracycline formulation in H-Ferritin nanocages as promising candidate to solve this unmet clinical need, thanks to its capability to increase anthracyclines efficacy while reducing their cardiotoxicity. Treating a murine model of HER2-positive breast cancer with co-administration of Trastuzumab and H-Ferritin anthracycline nanoformulation, we demonstrate an improved tumor penetration of drugs, leading to increased anticancer efficacy and reduced of cardiotoxicity.
Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model / F. Andreata, A. Bonizzi, M. Sevieri, M. Truffi, M. Monieri, L. Sitia, F. Silva, L. Sorrentino, R. Allevi, P. Zerbi, B. Marchini, E. Longhi, R. Ottria, S. Casati, R. Vanna, C. Morasso, M. Bellini, D. Prosperi, F. Corsi, S. Mazzucchelli. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 10:1(2020 Jul 10), pp. 11425.1-11425.10.
|Titolo:||Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model|
BONIZZI, ARIANNA (Co-primo)
CORSI, FABIO RUGGERO MARIA (Penultimo) (Corresponding)
MAZZUCCHELLI, SERENA (Ultimo) (Corresponding)
|Parole Chiave:||Breast cancer, Cardiotoxicity, Nanocages, Doxorubicin, H-Ferritin|
|Settore Scientifico Disciplinare:||Settore BIO/10 - Biochimica|
Settore MED/18 - Chirurgia Generale
|Progetto:||Nanocages di ferritina per il delivery di agenti antitumorali in carcinomi mammari primari ed in metastasi cerebrali|
|Data di pubblicazione:||10-lug-2020|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1038/s41598-020-68205-w|
|Appare nelle tipologie:||01 - Articolo su periodico|